61350-62-7

Usage

Uses

Used in Pharmaceutical Research:
(R)-N-[(phenylmethoxy)carbonyl]-2-pyrrolidinecarbonyl chloride is used as a key intermediate for the production of various pharmaceuticals and compounds. Its unique structure and reactivity allow for the creation of a wide range of molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-N-[(phenylmethoxy)carbonyl]-2-pyrrolidinecarbonyl chloride serves as a valuable building block for the development of complex organic molecules. Its versatility in reactions enables the synthesis of diverse chemical structures with potential applications in various industries.
Safety Note:
Due to its reactivity and potential hazards, (R)-N-[(phenylmethoxy)carbonyl]-2-pyrrolidinecarbonyl chloride should be handled with caution and in accordance with proper safety protocols to ensure the safety of researchers and the environment.

Upstream product

• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 79-37-8 oxalyl dichloride 
• 1148-11-4 N-carbobenzyloxyproline 
• 174740-81-9 N-benzyloxycarbonyl-(S)-(-)-2-azetidine-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 147-85-3 L-proline 
• 6404-31-5 Z-D-proline 
• 344-25-2 D-Prolin 

Downstream Products

• 14030-00-3 (2S)-2-[({(2S)-1-[(benzyloxy)carbonyl]tetrahydro-1H-pyrrol-2-yl}carbonyl)amino]propanoic acid 
• 73912-83-1 N-(1-benzyloxycarbonyl-L-prolyl)-L-serine 
• 2874-20-6 benzyloxycarbonyl-L-prolin-L-valin methyl ester 
• 85227-98-1 prolyl‐aspartate 
• 61596-44-9 N-(1-benzyloxycarbonyl-L-prolyl)-L-glutamic acid 
• 4526-86-7 Z-Pro-Gly-Gly-OEt 
• 19669-37-5 N-(1-benzyloxycarbonyl-L-prolyl)-L-tyrosine 
• 7360-23-8 Cbz-Pro-Pro-OH 
• 55878-58-5 Cbz-Pro-Hyp-OH 
• 135011-31-3 N^α-(1-benzyloxycarbonyl-L-prolyl)-L-histidine 
• 113332-46-0 N-benzyloxycarbonyl-L-prolyl-β-alanine 
• 56633-71-7 2-(S)-(2-diazo-1-oxoethyl)pyrrolidine-1-carboxylic acid benzyl ester 
• 5211-23-4 N-carbobenzyloxy-L-proline methyl ester 
• 143321-67-9 (S)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole 

Relevant academic research and scientific papers

3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS

The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions. Formula (I)

Diazophosphonates: Effective Surrogates for Diazoalkanes in Pyrazole Synthesis

Diazophosphonates, readily prepared from α-ketophosphonates by oxidation of the corresponding hydrazones in batch or in flow, are useful partners in 1,3-dipolar cycloaddition reactions to alkynes to give N-H pyrazoles, including the first intramolecular examples of such a process. The phosphoryl group imbues a number of desirable properties into the diazo 1,3-dipole. The electron-withdrawing nature of the phosphoryl stabilizes the diazo compound making it easier to handle, whilst the ability of the phosphoryl group to migrate readily in a [1,5]-sigmatropic rearrangement enables its transfer from C to N to aromatize the initial cycloadduct, and hence its facile removal from the final pyrazole product. Overall, the diazophosphonate acts as a surrogate for the much less stable diazoalkane in cycloadditions, with the phosphoryl group playing a vital, but traceless, role. The cycloaddition proceeds more readily with alkynes bearing electron-withdrawing groups, and is regiospecific with asymmetrical alkynes. The potential of diazophosphonates for use in bioorthogonal cycloadditions is demonstrated by their facile addition to strained alkynes.

Preparation method of water-soluble florfenicol amino acid salt

The invention discloses a preparation method of a water-soluble florfenicol amino acid ester salt. The method comprises the following steps: using florfenicol and N-Cbz-amino acid as the initial raw materials, carrying out acylating chlorination, esterifi

PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-A]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDE

The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.

BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST

The present invention discloses a benzimidazole-linked indole compound acting as novel divalent IAP antagonist, specifically disclosing the compound shown in fomulas (I) or a pharmaceutically acceptable salt thereof.

PROCESSES TO PRODUCE ACALABRUTINIB

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor.

Synthesis of 2-Fluoroalkyl 4-Substituted Azepanes

Synthesis of di- and tri-substituted fluoroalkylated azepanes was achieved by ring expansion of pyrrolidines via a regioselective attack of nucleophiles on a bicyclic azetidinium intermediate. A broad scope of azepanes, substituted at C4 and bearing a α-t

SUBSTITUTED PYRROLIDINES AND THEIR USE

The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

N-methyl-D-aspartate receptor modulators and methods of making and using same

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

A Manufacturing Process to an Intermediate in the Synthesis of Acalabrutinib

Optimization and application of the reported synthesis of (3-chloropyrazin-2-yl)methanamine 3 have provided a high yielding, fully telescoped procedure to key intermediate 5 in the synthesis of acalabrutinib.